Mallinckrodt (NYSE:MNK) Stock Rating Reaffirmed by Wells Fargo & Co

Wells Fargo & Co restated their hold rating on shares of Mallinckrodt (NYSE:MNK) in a report published on Monday morning, AnalystRatings.com reports.

Other analysts also recently issued research reports about the stock. BMO Capital Markets reaffirmed a market perform rating on shares of Mallinckrodt in a report on Thursday, September 5th. Stifel Nicolaus decreased their price objective on shares of Mallinckrodt from $20.00 to $8.00 and set a hold rating for the company in a report on Monday, September 9th. ValuEngine raised shares of Mallinckrodt from a sell rating to a hold rating in a report on Tuesday, December 3rd. Leerink Swann set a $2.00 price objective on shares of Mallinckrodt and gave the company a hold rating in a research report on Friday, September 6th. Finally, Jefferies Financial Group set a $2.00 target price on shares of Mallinckrodt and gave the stock a hold rating in a report on Friday, September 6th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $10.19.

Shares of NYSE:MNK opened at $3.36 on Monday. The company has a debt-to-equity ratio of 1.64, a current ratio of 1.07 and a quick ratio of 0.86. Mallinckrodt has a 1 year low of $1.43 and a 1 year high of $27.33. The company has a market cap of $274.97 million, a P/E ratio of 0.42, a PEG ratio of 0.03 and a beta of 2.59. The stock’s fifty day moving average price is $3.28 and its 200-day moving average price is $5.13.

Mallinckrodt (NYSE:MNK) last released its quarterly earnings data on Tuesday, November 5th. The company reported $2.07 EPS for the quarter, topping the consensus estimate of $1.98 by $0.09. Mallinckrodt had a positive return on equity of 24.36% and a negative net margin of 111.44%. The company had revenue of $743.70 million during the quarter, compared to the consensus estimate of $770.56 million. During the same period last year, the company earned $2.10 EPS. Mallinckrodt’s revenue for the quarter was down 7.0% on a year-over-year basis. On average, sell-side analysts anticipate that Mallinckrodt will post 8.59 earnings per share for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Amundi Pioneer Asset Management Inc. boosted its holdings in shares of Mallinckrodt by 126.4% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 40,149 shares of the company’s stock worth $873,000 after buying an additional 22,417 shares during the last quarter. Strs Ohio grew its position in Mallinckrodt by 78.9% during the second quarter. Strs Ohio now owns 84,100 shares of the company’s stock valued at $772,000 after buying an additional 37,100 shares during the period. Virginia Retirement Systems ET AL grew its position in Mallinckrodt by 96.2% during the second quarter. Virginia Retirement Systems ET AL now owns 56,300 shares of the company’s stock valued at $517,000 after buying an additional 27,600 shares during the period. Systematic Financial Management LP increased its holdings in Mallinckrodt by 76.3% during the second quarter. Systematic Financial Management LP now owns 95,110 shares of the company’s stock valued at $873,000 after buying an additional 41,165 shares during the last quarter. Finally, SG Americas Securities LLC increased its holdings in Mallinckrodt by 628.0% during the second quarter. SG Americas Securities LLC now owns 159,783 shares of the company’s stock valued at $1,467,000 after buying an additional 137,835 shares during the last quarter. 92.05% of the stock is owned by hedge funds and other institutional investors.

Mallinckrodt Company Profile

Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza.

Recommended Story: Cost of Debt

Analyst Recommendations for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.